ASX-listed Bioxyne has raised its FY2025 revenue guidance from $25 million to $28 million, pointing to strong domestic manufacturing performance and an imminent commercial capsule launch as the key factors behind the revision.
The announcement sent the company's share price climbing 23% to 3.2 cents per share.
Through its Breathe Life Sciences (BLS) subsidiary, Bioxyne recorded $12.6m in revenue during the first half of FY25, a 267% jump on the same period the prior year. Second-half sales are forecast to reach $15.4m, a 226% increase on the previous corresponding half.
The company identified Australian pharmaceutical manufacturing and supply as the "key driver of the growth".
BLS is moving toward commercial batch production of two MDMA capsule formulations and said it is making "significant progress" with operations in the UK and Germany, with further market updates expected shortly.
The upgraded outlook reflects both the continued expansion of Bioxyne's Australian operations and its anticipated entry into high-growth European markets.
Guidance for FY2026 is expected to be issued in August.
